Drugs / Difluoromethylornithine
Difluoromethylornithine
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial · 1 met primary | ||||||
| Phase 1 | NCT02384889 | Apr 2015 → Oct 2019 | type 1 diabetes mellitus | Indiana University | Completed | Met primary |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06219174 | Aug 2024 → Aug 2029 | non-small cell lung carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Suspended | No outcome recorded |
| Phase 24 trials · 1 met primary | ||||||
| Phase 2 | NCT04696029 | Mar 2021 → Mar 2028 expected | medulloblastoma | Giselle Sholler | Recruiting | No outcome recorded |
| Phase 2 | NCT02679144 | Feb 2016 → Feb 2028 expected | neuroblastoma | Giselle Sholler | Active not recruiting | Met primary |
| Phase 2 | NCT01636128 | Mar 2014 → Mar 2016 | — | Cancer Prevention Pharmaceuticals, Inc. | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT00204789 | Jul 2003 → Dec 2007 | disease related to solid organ transplantation, skin neoplasm | University of Wisconsin, Madison | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Difluoromethylornithine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00204789 ↗ |
| Known as | DFMO | “Difluoromethylornithine (DFMO) Chemoprevention of Skin Cancer in Organ Transplant Recipients” NCT00204789 ↗1“Difluoromethylornithine (DFMO)” NCT02679144 ↗ |
| Known as | DFMO, eflornithine | “DFMO, eflornithine” NCT01636128 ↗ |
| Known as | α-difluoromethylornithine | “In preclinical models, α-difluoromethylornithine (DFMO), an ornithine decarboxylase (ODC) inhibitor, delays the onset of type 1 diabetes (T1D) by reducing β cell stress.” PMID 37918404 ↗ Nov 2023 |
| Action | Inhibit | “α-difluoromethylornithine (DFMO), an ornithine decarboxylase (ODC) inhibitor” PMID 37918404 ↗ Nov 2023 |
| Route | Oral | “500 mg oral for 14 days, combined with sulindac for 15 days” NCT01636128 ↗ |